Actively Recruiting
Minto and Eleveld Remifentanil Target Controlled Infusion (TCI) Models: a Clinical Comparison
Led by University of Padova · Updated on 2025-12-15
100
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Remifentanil is commonly used as an opioid during general anesthesia. In recent years, several pharmacokinetic/pharmacodynamic (PK/PD) models for target-controlled infusion (TCI) have been developed, with the Eleveld model being one of the most recent and designed for broad applicability. The aim of this study is to compare the Eleveld TCI model with the routinely used Minto model, in order to evaluate potential differences in the predicted effect-site concentrations (CeR) required to achieve equivalent analgesia levels, as measured by qNOX (CONOX monitor) and the Analgesia Nociception Index (ANI). Post-Tetanic Count (PTC) was also assessed during the maintenance phase to investigate possible differences in nociceptive index responses between the two TCI models.
CONDITIONS
Official Title
Minto and Eleveld Remifentanil Target Controlled Infusion (TCI) Models: a Clinical Comparison
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female participants aged 18 to 80 years
- Undergoing general anesthesia with target-controlled infusion of propofol (Eleveld model)
- Using remifentanil target-controlled infusion with either the Minto or Eleveld model
You will not qualify if you...
- Presence of neurological disease
- Presence of psychiatric disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
ULSS2 Marca Trevigiana
Treviso, Italy, 31100
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here